20th May 2022
This International Clinical Trials Day, we spoke with Professor Marco Gerlinger. Professor Gerlinger and his team’s laboratory research focuses on understanding and overcoming drug resistance in bowel and gastro-oesophageal cancers, and identifying new and more effective ways to treat these cancers using immunotherapies and combination therapies.
Read more5th May 2022
We spoke with Dr John Riches, Clinical Senior Lecturer in the Centre for Haemato-Oncology at Barts Cancer Institute, Queen Mary University of London, about his team’s recent publication, which describes a new potential treatment target for a subset of lymphomas.
Read more29th April 2022
We would like to wish a very warm welcome to Dr Diu Nguyen who has recently joined the Barts Cancer Institute, Queen Mary University of London as a Lecturer and Group Leader. Dr Nguyen joins us from the Memorial Sloan Kettering Cancer Center in New York, USA, where she completed her postdoctoral training investigating the role of post-transcriptional regulation in normal and malignant cancer stem cells.
Read more11th February 2022
This International Day of Women and Girls in Science, Radhisha Kohombage, an MSc student at BCI, spoke to some fellow students, to hear more about their roles, inspirations, and advice for the next generation who would like to pursue a career in science.
Read more6th January 2022
Researchers from Barts Cancer Institute at Queen Mary University of London, the Moffitt Cancer Center and the University of Southern California, have developed a new method that measures subtle changes to the genetic code of cells (called DNA methylation) to study the dynamics of what happens to cells within our bodies over time. The new method, published in Nature Biotechnology, provides a way to measure the birth and death of human cells, making it possible to trace cell lineage and evolution.
Read more6th December 2021
Recent research from Barts Cancer Institute (BCI) at Queen Mary University of London has identified a novel therapeutic strategy to target lung cancer tumours that lack the gene LIMD1. We spoke with Professor Tyson V Sharp from BCI’s Centre for Cancer Cell & Molecular Biology, who led the study with Dr Sarah Martin, to find out more about the research and the significance of the findings.
Read more